An Operationally Seamless Phase 2/3 Randomized Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1

Brief description of study

The purpose of this research study is to learn about how an experimental drug combination (GS-1720 and GS-4182) affects the HIV-1 infection in your body and compare it to an approved treatment regimen (B/F/TAF, or Biktarvy). This experimental drug combination will be taken once a week by mouth. We are asking you to take part in this research study because you have undetectable HIV and are taking Biktarvy. Some people in this study will be randomly assigned to continue to take Biktarvy, and others will be randomly assigned to take the experimental weekly drug combination.


Clinical Study Identifier: s24-00311
ClinicalTrials.gov Identifier: NCT06544733


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.